Impact of Brokerage Rating on Neurocrine Biosciences, Inc.(NBIX)

Many Neurocrine Biosciences, Inc.(NBIX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Neurocrine Biosciences was Upgraded by Oppenheimer to Outperform on Jan 27, 2017. Neurocrine Biosciences was Initiated by Oppenheimer to Perform on Nov 22, 2016.

Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Dimitri E. Grigoriadis (Chief Research Officer) sold 727 shares at 43.13 per share price.On Feb 8, 2017, Haig P. Bozigian (Chief Development Officer) sold 963 shares at 43.14 per share price.On Feb 8, 2017, Kyle Gano (Chief Business Development Off) sold 727 shares at 43.15 per share price.

Neurocrine Biosciences Last issued its quarterly earnings results on Feb 14, 2017. The company reported $-0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $-0.55.During the same quarter in the previous year, the company posted $-0.34 EPS.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock has received a short term price target of $ 66.46 from 13 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $11.34. The higher estimate of target price is $96 , while the lower price target estimate is $55

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) witnessed a decline in the market cap on Tuesday as its shares dropped 1.45% or 0.61 points. After the session commenced at $42.1, the stock reached the higher end at $42.589 while it hit a low of $40.57. With the volume soaring to 1,275,170 shares, the last trade was called at $41.53. The company has a 52-week high of $55.15. The company has a market cap of $3,608 million and there are 86,871,313 shares in outstanding. The 52-week low of the share price is $32.18.

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The companys neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.


For any feedback and suggestions contact author at

Add Comment